跳转至内容
Merck
CN

R8883

Sigma-Aldrich

利福平

powder, γ-irradiated

别名:

3-(4-甲基-1-哌嗪基亚胺甲基)利福霉素SV, 利米定, 甲哌利福霉素

登录查看公司和协议定价

选择尺寸

关于此项目

经验公式（希尔记法）:
C43H58N4O12
化学文摘社编号:
13292-46-1
分子量:
822.94
Beilstein:
5723476
EC 号:
236-312-0
MDL编号:
MFCD00151389
UNSPSC代码:
12352200
PubChem化学物质编号:
329824041

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

生物来源

synthetic

无菌性

γ-irradiated

表单

powder

效能

≥880 μg per mg

颜色

orange to dark red

抗生素抗菌谱

Gram-negative bacteria
Gram-positive bacteria
mycobacteria

作用机制

protein synthesis | interferes

储存温度

−20°C

SMILES字符串

CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(\C=N\N5CCN(C)CC5)c(O)c4c3C2=O

InChI

1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1

InChI key

JQXXHWHPUNPDRT-WLSIYKJHSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

Chemical structure: macrolide

应用

Rifampicin is used as an inhibitor of transcription initiation, blocking initiation of RNA synthesis.

生化/生理作用

作用方式：通过与RNA聚合酶的β-亚基结合抑制RNA合成的起始。
抑制DNA和蛋白质组装成成熟的病毒颗粒。

包装

150mg

制备说明

在小瓶中直接用甲醇制备储存液 (25mg/mL)。

其他说明

Keep container tightly closed in a dry and well-ventilated place.Product is sensitive to light and moisture. Store under inert gas. Keep in a dry place.

象形图

Exclamation mark
GHS07

警示用语：

Warning

危险分类

Acute Tox. 4 Oral - Eye Irrit. 2 - Lact. - Skin Irrit. 2 - STOT SE 3

靶器官

Respiratory system

储存分类代码

11 - Combustible Solids

WGK

WGK 1

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

dust mask type N95 (US), Eyeshields, Gloves

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
SLBN1593V
051M8710V
051M8710
070M8701
097K8615

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Sandra V Kik et al.
The Journal of infectious diseases, 211 Suppl 2, S58-S66 (2015-03-15)
The potential available market (PAM) for new diagnostics for tuberculosis that meet the specifications of the high-priority target product profiles (TPPs) is currently unknown. We estimated the PAM in 2020 in 4 high-burden countries (South Africa, Brazil, China, and India)
Samy Figueiredo et al.
Antimicrobial agents and chemotherapy, 53(6), 2657-2659 (2009-03-25)
Two clonally related Acinetobacter baumannii isolates, A1 and A2, were obtained from the same patient. Isolate A2, selected after an imipenem-containing treatment, showed reduced susceptibility to carbapenems. This resistance pattern was related to insertion of the ISAba1 element upstream of
Rodney Dawson et al.
Lancet (London, England), 385(9979), 1738-1747 (2015-03-22)
New antituberculosis regimens are urgently needed to shorten tuberculosis treatment. Following on from favourable assessment in a 2 week study, we investigated a novel regimen for efficacy and safety in drug-susceptible and multidrug-resistant (MDR) tuberculosis during the first 8 weeks
Daniela Baldoni et al.
Antimicrobial agents and chemotherapy, 53(3), 1142-1148 (2008-12-17)
We investigated the activity of linezolid, alone and in combination with rifampin (rifampicin), against a methicillin-resistant Staphylococcus aureus (MRSA) strain in vitro and in a guinea pig model of foreign-body infection. The MIC, minimal bactericidal concentration (MBC) in logarithmic phase
Anil Koul et al.
Nature chemical biology, 3(6), 323-324 (2007-05-15)
The diarylquinoline R207910 (TMC207) is a promising candidate in clinical development for the treatment of tuberculosis. Though R207910-resistant mycobacteria bear mutations in ATP synthase, the compound's precise target is not known. Here we establish by genetic, biochemical and binding assays
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持